Wei wei Zhan

Dr. Wei wei Zhan


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
JZJianqiao Zhou
Jianqiao Zhou
LYLiXue Yin
LiXue Yin
XWXi Wei
Xi Wei
SZSheng Zhang
Sheng Zhang
YSYanYan Song
YanYan Song
WZWei wei Zhan
Wei wei Zhan

10 February 2017 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SXShujun Xia
Shujun Xia
RJRi Ji
Ri Ji
WZWei wei Zhan
Wei wei Zhan
The dysregulation of long noncoding RNAs (lncRNAs) has been identified in a variety of cancers. An increasing number of studies have found the critical role of lncRNAs in the regulation of cellular processes, such as proliferation, invasion and differentiation. Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) is a novel lncRNA that was primarily detected in papillary thyroid carcinoma. However, the biological function and molecular mechanism of lncRNA PTCSC3 in glioma are still unknown. The expression level of lncRNA PTCSC3 in human microglia and glioma cell lines was examined using quantitative real-time polymerase chain reaction (qRT-PCR). The influence of lncRNA PTCSC3 on cell proliferation were studied using the cell counting kit-8, and cell cycle and apoptosis were analyzed by flow cytometry assays. The migration and invasion abilities were investigated by transwell and wound healing assays. The target genes of lncRNA PTCSC3 were explored by qRT-PCR, immunofluorescence and western blot. LncRNA PTCSC3 was significantly downregulated in glioma cell lines. The overexpression of lncRNA PTCSC3 suppressed proliferation and induced apoptosis in U87 and U251 cells. Additionally, the overexpression of lncRNA PTCSC3 inhibited the migration and invasion of U87 and U251 cells. Moreover, lncRNA PTCSC3 inhibited the epithelial-mesenchymal transition of U87 cells. The study also demonstrated that LRP6, as a receptor of the Wnt/β-catenin pathway, was a target of lncRNA PTCSC3. By evaluating the expression levels of Axin1, active β-catenin, c-myc, and cyclin D1, the study indicated that lncRNA PTCSC3 inhibited the activation of the Wnt/β-cateninpathway through targeting LRP6. LncRNA PTCSC3 inhibits the proliferation and migration of glioma cells and suppresses Wnt/β-catenin signaling pathway by targeting LRP6. LncRNA PTCSC3 is a potential therapeutic target for treatment of glioma.

27 August 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
JZJianqiao Zhou
Jianqiao Zhou
YSYanYan Song
YanYan Song
WZWei wei Zhan
Wei wei Zhan
XWXi Wei
Xi Wei
SZSheng Zhang
Sheng Zhang
LYLiXue Yin
LiXue Yin

1 January 2019 in International Journal of Hyperthermia
Verified
Journal Article
Open access
WZWei Zhou
Wei Zhou
XNXiaofeng Ni
Xiaofeng Ni
SXShangyan Xu
Shangyan Xu
LZLu Zhang
Lu Zhang
YCYudong Chen
Yudong Chen
WZWei wei Zhan
Wei wei Zhan
Objectives: To compare the clinical outcomes of ultrasound-guided laser ablation (LA) and surgery for treatment of solitary papillary thyroid microcarcinoma (PTMC). Methods: A total of 81 consecutive patients with solitary PTMC were included in this retrospective study. Among them, 36 received LA and 45 underwent surgery. Surgery was performed by hemithyroidectomy with unilateral central neck dissection. The follow-up consisted of a physical examination, neck ultrasonography, chest X-ray or CT scan and thyroid function tests. The procedure time, hospital stay, complication and recurrence rates were compared between the two groups after treatment. Results: The follow-up period for the LA and surgical group were 49.2 ± 4.5 months (range, 30–54 months) and 48.5 ± 6.2 months (range, 24–54 months), respectively. The mean hospital stay and procedure time in the LA group were shorter than those in the surgical group. After LA, the largest diameter and average volume decreased from 4.7 ± 1.4 mm to 0.2 ± 0.8 mm, and from 43.2 ± 38.8 mm3 to 0.7 ± 4.1 mm3 (p < .05 for both), respectively. The complication rates and recurrence rates did not differ between the LA group (2.8% [1 of 36] and 5.6% [2 of 36]) and the surgical group (6.7% [3 of 45] and 6.7% [3 of 45]) (p > .05 for both). No distant metastasis occurred in the either group during the follow-up period. Conclusions: Compared with hemithyroidectomy with unilateral central neck dissection, ultrasound-guided LA was also a safe and effective therapy for treating solitary PTMC, and it may be considered as a treatment alternative for patients who are ineligible or refusal to undergo surgery.

1 January 2012
Verified
Book Chapter
Closed access
HLH.L. Lord
H.L. Lord
WZWei wei Zhan
Wei wei Zhan
JPJanusz Pawliszyn
Janusz Pawliszyn

10 November 2023 in Ultrasound in Medicine & Biology
Verified
Journal Article
Open access
JYJiejie Yao
Jiejie Yao
WZWei Zhou
Wei Zhou
SXShangyan Xu
Shangyan Xu
XJXiaohong Jia
Xiaohong Jia
JZJianqiao Zhou
Jianqiao Zhou
WZWei wei Zhan
Wei wei Zhan
The aim of the work described here was to assess the application of ultrasound (US) radiomics with machine learning (ML) classifiers to the prediction of axillary sentinel lymph node metastasis (SLNM) burden in early-stage invasive breast cancer (IBC). In this study, 278 early-stage IBC patients with at least one SLNM (195 in the training set and 83 in the test set) were studied at our institution. Pathologic SLNM burden was used as the reference standard. The US radiomics features of breast tumors were extracted by using 3D-Slicer and PyRadiomics software. Four ML classifiers-linear discriminant analysis (LDA), support vector machine (SVM), random forest (RF) and decision tree (DT)-were used to construct radiomics models for the prediction of SLNM burden. The combined clinicopathologic-radiomics models were also assessed with respect to sensitivity, specificity, accuracy and areas under the curve (AUCs). Among the US radiomics models, the SVM classifier achieved better predictive performance with an AUC of 0.920 compared with RF (AUC = 0.874), LDA (AUC = 0.835) and DT (AUC = 0.800) in the test set. The clinicopathologic model had low efficacy, with AUCs of 0.678 and 0.710 in the training and test sets, respectively. The combined clinicopathologic (C) factors and SVM classifier (C + SVM) model improved the predictive ability with an AUC of 0.934, sensitivity of 86.7%, specificity of 89.9% and accuracy of 91.0% in the test set. ML-based US radiomics analysis, as a novel and promising predictive tool, is conducive to a precise clinical treatment strategy.